← All trials
NCT04372017
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 14, 2020
- Primary completion
- Apr 20, 2022
- Completion date
- Apr 20, 2023
- First posted
- May 1, 2020
- Last posted
- May 18, 2020
- Enrollment
- 1739
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sanford HealthLead sponsor
- Sanford HealthStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.